Myriad Genetics (MYGN) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/15/22
Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care ConferenceGlobeNewsWire • 01/05/22
Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of ServiceGlobeNewsWire • 01/04/22
New Year's Resolutions: Americans Say Body & Mind Equally Important in Theory but Not in Practice, According to GeneSight® Mental Health Monitor Nationwide SurveyGlobeNewsWire • 12/15/21
The New Generation Gap: Nationwide Survey Finds Different Perspectives on Anxiety Between Parents, Young AdultsGlobeNewsWire • 12/15/21
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Value of Genetic Testing in Breast Cancer Risk Assessment and TreatmentGlobeNewsWire • 11/22/21
Myriad Genetics, Inc. (MYGN) CEO Paul Diaz on Q3 2021 Earnings Call TranscriptSeeking Alpha • 11/03/21
Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation PlansGlobeNewsWire • 11/02/21
Myriad Genetics to Release Third Quarter Financial Results on November 2, 2021GlobeNewsWire • 10/27/21
Americans' anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won't seek treatment according to the GeneSight® Mental Health Monitor nationwide surveyGlobeNewsWire • 10/11/21
Myriad Genetics Completes Sale of Myriad Autoimmune's Vectra Testing Business to LabCorpGlobeNewsWire • 09/13/21
Only 8% of people remain hopeful after depression medication fails them, according to GeneSight® Mental Health Monitor nationwide surveyGlobeNewsWire • 09/08/21
Myriad Genetics' (MYGN) CEO Paul Diaz on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/04/21